Sputum Eosinophils Predict Annual Remission of the Frequent Exacerbator Phenotype in COPD: A Prospective Cohort Study
Authors:
- 3 January 2026
- journal article
- Published by Springer Nature in Lung
- Vol. 204 (1) , 2
Abstract
The frequent-exacerbator (FE) phenotype guides COPD management, yet its year-to-year stability and the role of airway eosinophilia in FE remission are uncertain. In a single-center prospective cohort (n = 289), patients were classified as FE (≥ 2 moderate or ≥ 1 severe exacerbation in the prior year; n = 88) or non-FE (n = 201) and followed 12 months. FE patients were labeled FE-persistent or FE-remitted at 1 year. Clinical data, spirometry, CT, fractional exhaled nitric oxide (FeNO), blood counts, and induced-sputum cytology were collected. Logistic regression identified correlates of remission; ROC/AUC with bootstrap validation and calibration assessed models. FE prevalence was 30.4%; 58.0% of FE patients remitted. Compared with non-FE, FE had higher SE% and more eosinophilic/mixed sputum phenotypes. Within FE, remitters had better lung function and greater airway eosinophilia. Each 1% SE% increase independently predicted remission (OR 1.21, 95% CI 1.03-1.47); SE% ≥ 3% tripled the odds (OR 3.76, 95% CI 1.29-11.91). Prior severe exacerbations and CT-defined chronic bronchitis predicted persistence (ORs 0.21-0.27). Models showed good discrimination (AUC 0.785-0.799; bootstrap-corrected 0.750-0.773) and calibration (Brier 0.179). FE status is dynamic; over half remit within a year. Airway eosinophilia-especially SE% ≥ 3%-independently associates with FE remission, while prior severe exacerbations and CT-chronic bronchitis indicate persistence. Incorporating sputum cytology with history and imaging may enable earlier re-stratification and treatable-trait-guided COPD care.Keywords
Funding Information
- Clinical Research Program of Nanfang Hospital, Southern Medical University (2023CR008)
- National Natural Science Foundation of China (82370029 and 82570037)
- Guangdong Basic and Applied Basic Research Foundation (2023A1515010406)
This publication has 38 references indexed in Scilit:
- Treatable Traits as a Pathway to Remission in AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2025
- Identification of frequent acute exacerbations phenotype in COPD patients based on imaging and clinical characteristicsRespiratory Medicine, 2023
- Qualitative validation of the modified Medical Research Council (mMRC) dyspnoea scale as a patient-reported measure of breathlessness severityRespiratory Medicine, 2022
- Eosinophils in COPD—Current Concepts and Clinical ImplicationsThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Susceptibility to frequent exacerbation in COPD patients: Impact of the exacerbations history, vaccinations and comorbidities?Respiratory Medicine, 2020
- Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohortThe Lancet Respiratory Medicine, 2017
- Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohortThe Lancet Respiratory Medicine, 2017
- The COPD Assessment TestChest, 2016
- Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsThe Lancet Respiratory Medicine, 2015
- Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2000